Cirtuvivint is under clinical development by Biosplice Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cirtuvivint’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cirtuvivint overview
Cirtuvivant is under development for the treatment of acute myelocytic leukemia and B-cell chronic lymphocytic leukemia. The therapeutic candidate is formulated as tablet and administered through oral route. The drug candidate acts by targeting dual specificity protein kinase CDC-like kinase (CLK1-4) and dual specificity tyrosine phosphorylation regulated kinase (DYRK 1-4).
The drug candidate was also under development for the treatment of pancreatic cancer and gastric cancer.
It was also under development for the treatment of solid tumors including castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), relapsed acute myeloid leukemia, refractory acute myeloid leukemia, myelodysplastic syndrome, colorectal cancer (CRC), endometrial cancer, ovarian cancer and hepatocellular carcinoma.
Biosplice Therapeutics overview
Biosplice Therapeutics is a biotechnology company that develops CLK/DYRK kinase based small-molecule drugs for musculoskeletal diseases, inflammation, and oncology disorders. It is investigating Cirtuvivint (SM08502) inhibitor to treat metastatic castration-resistant prostate cancer, heme malignancies, and solid tumors; lorecivivint (SM04690) against hip, shoulder and knee osteoarthritis and degenerative disc diseases. Biosplice Therapeutics is also evaluating DYRK1A (dual specificity tyrosine-phosphorylation-regulated kinase 1A), an oral brain penetrant for the treatment of Alzheimer’s disease, traumatic brain injury and select therapies. The company’s scientific platform is based on biological discoveries that govern tissues specialization. Biosplice Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of Cirtuvivint’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
